Mortality from COVID-19 in patients with lung cancer

Abstract

The World Health Organization declared coronavirus infectious disease-2019 (COVID-19) linked to the severe acute respiratory syndrome (SARS-CoV-2), a global pandemic in March 2020. The pandemic outbreak has led to the most unprecedented and catastrophic loss of human life in the recent history. As of January 2021, there were more than 100 million cases of COVID-19 and more than two million deaths worldwide. Compared to the general population, patients with cancer are at a higher risk of poor outcomes from COVID-19. In large cohort studies, mortality from COVID-19 in patients with cancer can be as high as 40%. In addition to clinical variables (older age, male sex, and co-morbidities) that are associated with mortality in general population, cancer patients are uniquely vulnerable to severe COVID-19 due to immunosuppression from cancer and its therapy, and disruption of routine clinical care. Among patients with cancer, the lung cancer population is at a higher risk of poor outcomes and mortality from COVID-19 for several reasons. For instance, lung is the main target organ in COVID-19 that can lead to respiratory failure, patients with lung cancer have baseline poor lung function from chronic obstructive pulmonary disorder and smoking. In addition, some of the lung cancer treatment side-effects like pneumonitis, may obscure the diagnosis of COVID-19. In this article, we systematically review the most impactful cohort studies published to date in patients with cancer and COVID-19. We describe the rates of mortality in patients with cancer and COVID-19 with a special focus on the lung cancer population. We also summarize the factors associated with poor outcomes and mortality in patients with lung cancer and COVID-19.

Keywords

Coronavirus / COVID-19 / lung cancer / mortality

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[2] CDC COVID data tracker.Available from: https://covid.cdc.gov/covid-data-tracker/#county-view [Last accessed on 26 May 2021] PMCID:PMC7842812

[3] Williamson EJ,Bhaskaran K.Factors associated with COVID-19-related death using OpenSAFELY.Nature2020;584:430-6

[4] Docherty AB,Green CA.ISARIC4C investigatorsFeatures of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.BMJ2020;369:m1985 PMCID:PMC7243036

[5] Malik P,Mehta D.Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis.BMJ Evid Based Med2021;26:107-8 PMCID:PMC7493072

[6] Ruan Q,Wang W,Song J.Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.Intensive Care Med2020;46:846-8 PMCID:PMC7080116

[7] Kuderer NM,Shah DP.Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.Lancet2020;395:1907-18 PMCID:PMC7255743

[8] Lee LY,Angelis V.COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.Lancet2020;395:1919-26 PMCID:PMC7255715

[9] Dai M,Liu M.Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak.Cancer Discov2020;10:783-91 PMCID:PMC7309152

[10] Mehta V,Kabarriti R.Case fatality rate of cancer patients with COVID-19 in a New York hospital system.Cancer Discov2020;10:935-41 PMCID:PMC7334098

[11] Garassino MC,Huang L.COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.Lancet Oncol2020;21:914-22 PMCID:PMC7292610

[12] Guan WJ,Hu Y.China Medical Treatment Expert Group for Covid-19Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med2020;382:1708-20 PMCID:PMC7092819

[13] Yang K,Huang C.Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study.Lancet Oncol2020;21:904-13 PMCID:PMC7259917

[14] Yarza R,Paredes D.SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.Eur J Cancer2020;135:242-50 PMCID:PMC7275164

[15] Assaad S,Fournier ML.High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.Eur J Cancer2020;135:251-9 PMCID:PMC7275994

[16] Luo J,Preeshagul IR.COVID-19 in patients with lung cancer.Ann Oncol2020;31:1386-96 PMCID:PMC7297689

[17] Liang W,Chen R.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.Lancet Oncol2020;21:335-7 PMCID:PMC7159000

[18] Luo J,Egger JV,Wolchok JD.Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers.Cancer Discov2020;10:1121-8 PMCID:PMC7416461

[19] AACR COVID-19 and Cancer Virtual Meeting: The distressing intersection of the pandemic and noncommunicable diseases - American Association for Cancer Research (AACR). Available from: https://www.aacr.org/professionals/blog/aacr-covid-19-and-cancer-virtual-meeting-the-distressing-intersection-of-the-pandemic-and-noncommunicable-diseases/ [Last accessed on 26 May 2021]

[20] Horn L,Torri V.Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy on survival.J Clin Oncol2020;38:LBA111

[21] AACR virtual meeting: COVID-19 and cancer. Available from: https://www.aacr.org/meeting/aacr-virtual-meeting-covid-19-and-cancer/program/ [Last accessed on 26 May 2021]

[22] International Association for the Study of Lung Cancer. Available from: https://library.iaslc.org/conference-program?product_id=20&author=&category=&date=&session_type=&session=&presentation=&keyword=umit [Last accessed on 26 May 2021]

[23] Desai A,Advani S.Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies.Cancer2021;127:1459-68

[24] Zhang H,He T.Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis.J Natl Cancer Inst2021;113:371-80 PMCID:PMC7665647

[25] Yekedüz E,Ürün Y.A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19.Eur J Cancer2020;141:92-104 PMCID:PMC7538140

[26] ASCO COVID-19 guidelines. Available from: https://www.asco.org/sites/new-www.asco.org/files/content-files/2020-ASCO-Guide-Cancer-COVID19.pdf [Last accessed on 26 May 2021]

[27] Cancer Patient Management During the COVID-19 Pandemic. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic [Last accessed on 26 May 2021]

[28] Coronavirus disease 2019 (COVID-19) resources for the Cancer Care Community. Available from: https://www.nccn.org/covid-19/ [Last accessed on 26 May 2021]